Amicus Therapeutics Inc.
Amicus Therapeutics Reports Strong Q2 2024 Results and Raises Full-Year Guidance
Summary
Amicus Therapeutics, Inc. announced its Q2 2024 financial results, reporting total revenue of $126.7 million, a 34% increase year-over-year. The company also raised its full-year 2024 revenue growth guidance to 26%-31% at CER and narrowed its non-GAAP operating expense guidance to $345M to $360M. The company achieved non-GAAP profitability in Q2 and H1 2024 and expects acceleration in H2. Key highlights include robust revenue growth driven by Galafold and strong performance of Pombiliti + Opfolda. Amicus will host a conference call on August 8, 2024, to discuss these results.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement